rTMS Effect in Functional Psychogenic Movement Disorders Applied Alone Then Combined With Hypnotherapy

Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Functional Psychogenic Movement Disorders Followed by a Feasibility Study of a Hypnotherapy Treatment as Adjuvant Therapy.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02471066

Acronym

MOVHYSTIM

Enrollment

Registered

2015-06-12

Start date

2015-04-30

Completion date

2018-01-31

Last updated

2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Movement Disorders

Brief summary

The management of functional psychogenic movement disorders (FNPMD) is challenging for neurologists and psychiatrists and only comprehensive multidisciplinary treatment programme can be worthwhile for these patients (Moene et al 2002). Recent functional magnetic resonance imaging studies have demonstrated abnormalities in motor control at cortical level, hyperactivity of limbic system and disturbance of connectivity between these two systems leading to a lack of self-agency, (Voon et al 2010,2011).Two recent studies suggested a possible therapeutic effect of transcranial magnetic stimulation (TMS) in FNPMD (Dakotakis 2011, Garcin, 2013). In this protocol our objectives are twofold : 1. to compare the effect of 5 consecutive daily sessions of rTMS on FNPMD in a double-blind randomized controlled study 2. to study the effect of 3 weekly hypnosis sessions combined with rTMS in FNPMD

Interventions

DEVICErTMS

* Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham * Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Man or woman with FNPMD for at least 2 months, * diagnosed from clinical Diagnostic and Statistical Manual V conversive somatoform troubles and Gupta & Lang (2009) and Edwards & Bahtia 2012 neurological clinical criteria

Exclusion criteria

* Severe progressive psychiatric disorders * Cardiac pace-maker * Metallic prosthesis * Cochlear implants * Previous neurosurgery * Epilepsy * Severe cardiac disease * Alcohol or toxic abuse for the last 12 months * Drugs such clozapine, bupropion, methadone or theophylline

Design outcomes

Primary

Measure	Time frame
Changes of Psychogenic Movement Disorder Rating Scale (PMDRS= Hinson score between baseline and one month after rTMS treatment	Inclusion and 1 month later

Secondary

Measure	Time frame
Clinical Global Impression-Severity scale (CGI-SEVERITY/CGI-I/CGI-S)	inclusion, inclusion + 5 days, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.
Hospital Anxiety and Depression Scale (HAD/HDRS)	inclusion, inclusion + 1 month, inclusion + 6 months, inclusion + 12 months.
Quality of Life (SF-36)	inclusion, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.
Temperament and Character Inventory (TCI)	inclusion, inclusion + 12 months.
Pain scale (VAS)	: inclusion, inclusion + 5 days, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026